UNITED STATESSECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report: August 8, 2014
Commission File Number 333-133347
Peptide Technologies, Inc.
(Exact name of registrant as specified in its charter)
Nevada 98-0479983
--------------------------------- ---------------------
State or other jurisdiction of (I.R.S. Employer
incorporation or organization Identification No.)
601 Union Street, Two Union Square, 42nd Floor, Seattle, Washington 98101
-------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (206) 236-9555
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions: [ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
SECTION 5 - CORPORATE GOVERNANCE AND MANAGEMENT
Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Resignation of Director and Officer Effective August 8, 2014, a letter of
resignation tendered by Scott McKinley as Director of the Company and as Chief
Executive Officer and Chief Operating Officer was accepted. Upon his
resignation, Scott McKinley relinquished 50,000,000 shares of common stock to
Baxter Koehn (45,000,000 shares) and Dennis Cox (5,000,000 shares) upon their
acceptance of the positions of Chief Executive Officer and President
respectively for the Company.
Appointment of Officers
Effective August 8, 2014, Baxter Koehn has been appointed Chief Executive
Officer of the Company until he resigns or his successors be elected by the
shareholders of the Company or appointed by the Board of Directors. Baxter Koehn
is also presently a member of the Board of Directors serving as Chief Financial
Officer and Secretary/Treasurer of the Company
Effective August 8, 2014, Mr. Selwyn Dennis Cox has been appointed President of
the Company to serve until he resign or his successors be elected by the
shareholders of the Company or appointed by the Board of Directors. Dennis Cox
is also presently a member of the Board of Directors of the Company.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned, hereunto duly authorized.
PEPTIDE TECHNOLOGIES, INC.
By: /s/ Baxter Koehn
Baxter Koehn
Chairman of the Board
Date: August 8, 2014
3